Pharmacokinetics and Tolerability of a Single 15mg Meloxicam Dose Injected Intramuscularly Compared to a Single Oral 15 mg Meloxicam Tablet in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study.
Pharmacokinetics and Tolerability of a Single 15mg Meloxicam Dose Injected Intramuscularly Compared to a Single Oral 15 mg Meloxicam Tablet in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study.
Study to investigate the pharmacokinetics and tolerability of an intramuscular 15 mg meloxicam injection in comparison to the 15 mg oral tablet
Inclusion Criteria:
Exclusion Criteria:
Any findings of the medical examination (including laboratory, blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
Surgery of the gastro-intestinal tract ( except appendectomy)
Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
Chronic or relevant acute infections
Hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents
Intake of drugs with a long half-life (>24 hours) (≤ 1 month prior to administration or during the trial)
Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial)
Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial)
Smoker (>= 10 cigarettes or >= 3 cigars or >= 3 pipes/day)
Inability to refrain from smoking on study days
Known alcohol abuse
Known drug abuse
Blood donation (≤ 1 month prior to administration)
Excessive physical activities (≤ 5 days prior to administration)
History of hemorrhagic diatheses
History of gastro-intestinal ulcer, perforation or bleeding
History of bronchial asthma
For female subjects: